MCMonika Chaszczewska-Markowska

Monika Chaszczewska-Markowska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Monika Chaszczewska-Markowska has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Katarzyna Bogunia-Kubik

    Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland

    6 shared publications
  • Aleksandra Butrym

    Department of Internal Diseases, Occupational Medicine, Hypertension and Clinical Oncology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland

    2 shared publications
  • Grzegorz Mazur

    Department of Emergency Medical Service, Wroclaw Medical University, 51-616 Wroclaw, Poland

    2 shared publications
  • Maciej Ugorski

    Department of Biochemistry and Molecular Biology, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland

    2 shared publications
  • Adam Opolski

    1 shared publication
  • Agnieszka Chryplewicz

    Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland

    1 shared publication

Latest Publications

  • Open Access

    Polystyrene nanoplastics induce mitochondrial dysfunction and stress responses in human PBMCs

    by Aleksandra G. Bilska, Monika Chaszczewska-Markowska, Paweł Gajdanowicz, Anna Kosowska, Magdalena Pietrzak, Mohamed H. Shamji, Marek Jutel, Magdalena Zemelka-Wiącek


  • Open Access

    Bone marrow-derived macrophages loaded with boron carbide nanoparticles as selective boron carriers for crossing the blood-brain barrier toward the glioma microenvironment for boron neutron capture therapy

    by Anna Rudawska, Agnieszka Szczygieł, Katarzyna Węgierek-Ciura, Jagoda Mierzejewska, Dawid Kozień, Paulina Żeliszewska, Monika Chaszczewska-Markowska, Piotr Rusiniak, Katarzyna Wątor, Zbigniew Pędzich, et al.

    Background: Boron neutron capture therapy (BNCT) is a type of targeted radiotherapy that destroys boron-containing cancer cells using a neutron beam. It is intended for the treatment of patients with tumors that are resistant to conventional treatment, inoperable and recurrent. Therefore, it represents a promising therapy for the treatment of glioblastoma multiforme, the most aggressive stage IV cancer. To ensure high efficacy of BNCT, it is necessary to use selective boron carriers that deliver therapeutic doses of the boron-10 isotope to the tumor site, demonstrate a lack of systemic toxicity, and, most importantly, cross the blood-brain barrier. In our studies, we propose using bone marrow-derived macrophages as cellular carriers of boron carbide nanoparticles to selectively deliver boron-10 to the tumor microenvironment. Macrophages can efficiently engulf foreign particles, migrate and accumulate at the tumor site, as well as cross the blood-brain barrier, making them extremely promising boron carriers for BNCT. Results: Bone marrow-derived macrophages in three polarization states (M0, M1, and M2) demonstrated a high uptake ability of boron carbide nanoparticles at a concentration of 100 µg/ml during 24-hour incubation. The highest boron concentration was detected in M1 macrophages, resulting in the greatest inhibition of viability and slower spontaneous migration of this population compared to other types of macrophages. Nevertheless, all macrophage populations (M0, M1, and M2) loaded with boron carbide nanoparticles migrated comparably through the brain endothelial cell layer, mimicking the blood-brain barrier, toward the CCL2-rich supernatant of GL-261 glioma cells. Furthermore, macrophages with nanoparticles did not affect the viability of glioma spheroids after 6 days of co-culture, in contrast to macrophages without nanoparticles, which increased the survival of tumor cells. Importantly, M1 macrophages did not repolarize toward the M2 phenotype during co-culture, as evidenced by the stable expression of CD206 in these cells. In addition, M2 macrophages loaded with B 4 C nanoparticles showed lower CD206 expression after contact with spheroids compared to this macrophage population without nanoparticles. Conclusions: Bone marrow-derived macrophages loaded with boron carbide nanoparticles showed great potential for use in BNCT as boron carriers crossing the blood-brain barrier toward the glioma microenvironment.

  • Open Access

    Polymorphisms within Genes Coding for IL‐17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis

    by Joanna Wielińska, Jerzy Świerkot, Katarzyna Kolossa, Bartosz Bugaj, Monika Chaszczewska-Markowska, Sławomir Jeka, Katarzyna Bogunia-Kubik

    IL‐17A and IL‐17F together with their coreceptor (IL‐17RA/RC) were reported to play a significant role in the pathogenesis of spondyloarthritis. The group of axial spondyloarthritis comprises ankylosing spondylitis (AS), a rheumatic disease characterized by chronic inflammation of the joints in the spine. This study is aimed at investigating IL-17A, IL-17F, IL-17RA, and IL-17RC polymorphisms as potential biomarkers of disease susceptibility, clinical parameters, and anti‐TNF treatment outcome in a cohort of Polish ankylosing spondylitis patients. In total, 328 subjects, including 138 AS patients and 190 healthy volunteers, participated in the study. Genotyping of IL-17A rs2275913 (G/A), IL-17F rs763780 (A/G), IL-17RA rs4819554 (A/G), and IL-17RC rs708567 (G/A) was performed on real‐time PCR instrument using LightSNiP assays. No significant differences were revealed in genotype and allele distribution between patients and controls despite the association of the IL-17RC rs708567 AA homozygosity with the earlier onset of the disease. Moreover, some relationships between IL-17F rs763780 and IL-17RA rs4819554 polymorphisms with clinical parameters related to the disease activity and anti‐TNF treatment outcome were observed. IL-17F rs763780 G allele was found to be associated with high disease activity and BASDAI after 6 months and poor response to the treatment while higher VAS values were more common among IL-17RA rs4819554 G variant carriers. In conclusion, the IL-17F rs763780 polymorphism should be considered as a promising biomarker of disease activity and anti‐TNF treatment outcome. The IL-17RA rs48419554 G allele may serve as a potential marker of disease severity in Polish AS patients.


  • ECCR1 and NFKB2 Polymorphisms as Potential Biomarkers of Non-small Cell Lung Cancer in a Polish Population

    by Monika Chaszczewska-Markowska, Monika Kosacka, Agnieszka Chryplewicz, Tomasz Dyła, Anna Brzecka, Katarzyna Bogunia-Kubik

    Background/Aim: Although genetic factors are presumed to account only for a part of the inter-individual variation in lung cancer susceptibility, the results are conflicting and there are no data available regarding the Polish population. We, therefore, performed a case-control study to investigate the association of seven selected single nucleotide polymorphisms (SNPs), in genes coding for excision repair cross-complimentary group 1 (ERCC1: rs11615, rs3212986, rs2298881), nuclear factor ĸB (NFKB2: rs7897947, rs12769316), bone morphogenetic protein 4 (BMP4: rs1957860), complement receptor 1 (CR1: rs7525160) and del/ins polymorphism in the family hypoxia inducible factor 2 gene (EGLN2: rs10680577), with non-small cell lung cancer (NSCLC) risk. Materials and Methods: Real-time PCR with melting curve analysis was used for genotyping of NSCLC patients and healthy individuals of Polish origin. Results: The ERCC1 rs11615 T allele and rs3212986 GG homozygosity were found to be associated with a higher risk of developing NSCLC. In addition, NFKB2 rs12769316 GG homozygosity was more frequently detected among male patients than controls, while no significant differences were found between the five polymorphisms. Conclusion: ERCC1 polymorphisms may affect NSCLC risk in the Polish population, while the NFKB2 variant may be a possible marker of the disease in males.


  • G-CSF administration favours SDF-1 release and activation of neutrophils and monocytes in recipients of autologous peripheral blood progenitor cells

    by Katarzyna Gębura, Aleksandra Butrym, Monika Chaszczewska-Markowska, Tomasz Wróbel, Kazimierz Kuliczkowski, Katarzyna Bogunia-Kubik


  • Genetically determined enlargement of carotid body evaluated using computed angiotomography

    by Przemysław Jaźwiec, Paweł Gać, Monika Chaszczewska-Markowska, Katarzyna Bogunia-Kubik, Grzegorz Mazur, Rafał Poręba


  • Open Access

    Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma

    by Aleksandra Butrym, Piotr Łacina, Justyna Rybka, Monika Chaszczewska-Markowska, Grzegorz Mazur, Katarzyna Bogunia-Kubik

    Multiple myeloma (MM) is a plasma-cell malignancy derived from an early precursor of the B-cell lineage characterised by bone-marrow infiltration, lytic bone lesions, and the presence of a monoclonal protein in serum and/or urine. Interferon regulatory factor 4 (IRF4) is a critical transcriptional regulator in B-cell development and function that is required during immune response for lymphocyte activation and the generation of immunoglobulin-secreting plasma cells. Immunomodulatory drugs, derivatives of thalidomide, are commonly used in therapy against MM. They are known to target a protein called cereblon (CRBN); however, the exact mechanism remains unknown. The present study aimed to assess the association of two (rs12203592 and rs872071) polymorphisms within the IRF4 gene and two (rs711613 and rs1045433) in the CRBN gene with MM susceptibility, progression, and response to treatment. For this purpose, 144 MM patients and 126 healthy individuals were genotyped for the IRF4 and CRBN alleles. The presence of the IRF4 (rs872071) G allele was more frequently detected in patients than healthy individuals (OR 1.78; P = 0.034), and this relationship was especially pronounced in women (OR 2.83; P = 0.012). The CRBN (rs711613) A allele-carriers were better responders to the treatment (P = 0.012), in particular to thalidomide including therapy (P = 0.023). These results underline the prognostic significance of the IRF4 and CRBN polymorphisms in patients with MM.


  • Open Access

    The renin-angiotensin-aldosterone system (RAAS) – physiology and molecular mechanisms of functioning

    by Monika Chaszczewska-Markowska, Maria Sagan, Katarzyna Bogunia-Kubik

    Secretion of renin juxtaglomerular cells into bloodstream initiates activation of an enzymatic-hormonal cascade known as the RAAS (renin - angiotensin - aldosterone system). As a result, blood pressure is increased by the means several interrelated mechanisms. Mechanism of Zjednoczoaction of this system has been known for decades, but a few previously unknown components were recently added, such as ACE-2 and Ang(1-7), and their role often seems to be opposite to that of the conventional components. Local tissue systems also have important biological functions. They operate largely independently of the systemic activity, and their activity is observed primarily in the kidney, heart, in blood vessels, adrenal gland and nervous system. Angiotensin-2 (Ang-2), the main RAAS effector, has a wide scope of action, and thus abnormalities in its functioning have many consequences. Excessive activation is accompanied by chronic inflammation, as Ang-2 stimulates inflammatory mediators. As a result, degenerative processes and atherosclerosis are initiated. RAAS imbalance is associated with the most common diseases of civilization, such as cardio-vascular diseases, diabetes, kidney diseases, preeclampsia, osteoporosis and even neurodegenerative diseases. Many of these pathological processes are attributed to the excessive activation of tissue RA system. Therapeutic strategies based on inhibition of the RAAS are commonly used mainly in the treatment of hypertension and other cardiovascular disorders. The benefits of this class of drugs is primarily a decrease in blood pressure, but also the suppression of inflammatory processes and other pathological phenomena resulting from excessive activation of the RAAS. For that reason, some consider to use RAAS inhibitors in other diseases, e.g. Parkinson's disease. Further studies give hope for the improvement of RAAS inhibitor therapy and the development of new therapeutic strategies.


  • Liposomal formulation of 5-fluorocytosine in suicide gene therapy with cytosine deaminase – for colorectal cancer

    by Monika Chaszczewska-Markowska, Katarzyna Stebelska, Aleksander Sikorski, Janusz Madej, Adam Opolski, Maciej Ugorski